Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2165-3070
Debt
Debt-to-Equity Ratio0.13
Current Ratio5.60
Quick Ratio5.57
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.27 million
Price / Sales48.10
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book2.19
Profitability
EPS (Most Recent Fiscal Year)($0.78)
Net Income$-34,160,000.00
Net Margins-1,429.80%
Return on Equity-90.64%
Return on Assets-67.19%
Miscellaneous
Employees8,406
Outstanding Shares62,390,000
Affimed (NASDAQ:AFMD) Frequently Asked Questions
What is Affimed's stock symbol?
Affimed trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed's earnings last quarter?
Affimed NV (NASDAQ:AFMD) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.18) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.18). The biopharmaceutical company earned $0.65 million during the quarter, compared to analysts' expectations of $0.54 million. Affimed had a negative net margin of 1,429.80% and a negative return on equity of 90.64%. View Affimed's Earnings History.
When is Affimed's next earnings date?
What price target have analysts set for AFMD?
3 equities research analysts have issued 1 year price objectives for Affimed's shares. Their forecasts range from $2.50 to $7.00. On average, they expect Affimed's share price to reach $4.75 in the next twelve months. View Analyst Ratings for Affimed.
Who are some of Affimed's key competitors?
Some companies that are related to Affimed include Albireo Pharma (ALBO), Mersana Therapeutics (MRSN), GTX (GTXI), Unum Therapeutics (UMRX), American Brivision (Holding) (ABVC), Achillion Pharmaceuticals (ACHN), Savara (SVRA), Tyme Technologies (TYME), Seres Therapeutics (MCRB), Corvus Pharmaceuticals (CRVS), MediciNova (MNOV), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Syros Pharmaceuticals (SYRS) and Kala Pharmaceuticals (KALA).
Who are Affimed's key executives?
Affimed's management team includes the folowing people:
- Dr. Adi Hoess M.D., Ph.D., CEO, MD & Member of Management Board (Age 56)
- Dr. Florian H. M. Fischer MBA (Dipl.-Kfm.), Ph.D., MD, CFO & Member of Management Board (Age 50)
- Prof. Melvyn Little Ph.D., Founder and Consultant
- Dr. Wolfgang Fischer, Chief Operating Officer and Interim CMO
- Dr. Martin Treder, Chief Scientific Officer (Age 48)
Has Affimed been receiving favorable news coverage?
News headlines about AFMD stock have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Affimed earned a news sentiment score of 0.22 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.45 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Affimed's major shareholders?
Affimed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.24%), Millennium Management LLC (4.10%), Sabby Management LLC (0.68%), Eversept Partners LLC (0.62%), CVI Holdings LLC (0.58%) and Dimensional Fund Advisors LP (0.51%). View Institutional Ownership Trends for Affimed.
Which institutional investors are buying Affimed stock?
AFMD stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, NEA Management Company LLC, Sabby Management LLC, Eversept Partners LLC, CVI Holdings LLC, Iguana Healthcare Management LLC, Point72 Asset Management L.P. and Sofinnova Ventures Inc. View Insider Buying and Selling for Affimed.
How do I buy shares of Affimed?
Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed's stock price today?
One share of AFMD stock can currently be purchased for approximately $1.75.
How big of a company is Affimed?
Affimed has a market capitalization of $107.62 million and generates $2.27 million in revenue each year. The biopharmaceutical company earns $-34,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Affimed employs 8,406 workers across the globe.
How can I contact Affimed?
Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]
MarketBeat Community Rating for Affimed (AFMD)
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
